Get the Stockscreener App
7.75
2.52%
-0.20
After Hours:
7.95
0.20
+2.58%
Zevra Therapeutics Inc stock is traded at $7.75, with a volume of 1.82M.
It is down -2.52% in the last 24 hours and down -34.10% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$7.95
Open:
$7.92
24h Volume:
1.82M
Relative Volume:
1.44
Market Cap:
$435.05M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-6.0078
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-13.41%
1M Performance:
-34.10%
6M Performance:
-2.15%
1Y Performance:
+2.11%
1-Day Range:
$7.69
$7.97
1-Week Range:
$7.69
$8.95
52-Week Range:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
7.75 | 447.96M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Sees Significant Increase in Short Interest - MarketBeat
Woodline Partners LP Acquires 476,032 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Adage Capital Partners GP L.L.C. Reduces Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Does Zevra Therapeutics Inc. have high return on assets2025 Market Overview & Growth Oriented Trading Recommendations - Lancaster City Council
Is Zevra Therapeutics Inc. stock a good dividend stockBuy Signal & Reliable Momentum Entry Alerts - Lancaster City Council
Moving Average Crossover Confirms Uptrend in Zevra Therapeutics Inc.July 2025 Intraday Action & Community Consensus Picks - beatles.ru
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash - simplywall.st
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless - 富途牛牛
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives $23.71 Consensus PT from Analysts - MarketBeat
Is Zevra Therapeutics Inc. a strong growth stockWeekly Trade Report & Low Drawdown Momentum Trade Ideas - خودرو بانک
Retirement Planning Co of New England Inc. Purchases 35,348 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics, Inc. $ZVRA Shares Sold by Nantahala Capital Management LLC - MarketBeat
Is Zevra Therapeutics Inc. in a long term uptrend2025 Key Lessons & Real-Time Chart Pattern Alerts - خودرو بانک
What’s the recovery path for long term holders of Zevra Therapeutics Inc.Market Activity Recap & Free Community Consensus Stock Picks - Newser
Is Zevra Therapeutics Inc. a good ESG investmentGap Down & Free Verified High Yield Trade Plans - خودرو بانک
What analysts say about Zevra Therapeutics Inc. stockWeekly Profit Report & High Return Trade Opportunity Guides - خودرو بانک
Quantitative breakdown of Zevra Therapeutics Inc. recent moveQuarterly Investment Review & Long-Term Safe Return Strategies - Newser
Measuring Zevra Therapeutics Inc.’s beta against major indicesMarket Weekly Review & Precise Swing Trade Alerts - Newser
Using Python tools to backtest Zevra Therapeutics Inc. strategiesMarket Performance Summary & Advanced Technical Analysis Signals - Newser
Wellington Management Group LLP Makes New $1.05 Million Investment in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Inc. stock retracement – recovery analysisSell Signal & Safe Entry Momentum Tips - Newser
Using data models to predict Zevra Therapeutics Inc. stock movementStock Surge & Free Technical Confirmation Trade Alerts - Newser
Does Zevra Therapeutics Inc. qualify in momentum factor screeningWeekly Profit Report & Expert Curated Trade Setup Alerts - Newser
Volume spikes in Zevra Therapeutics Inc. stock – what they meanTrade Risk Report & Safe Entry Trade Signal Reports - Newser
What recovery options are there for Zevra Therapeutics Inc.July 2025 Market Mood & Reliable Entry Point Alerts - Newser
Zevra Therapeutics Presents Positive New Data Supporting - GlobeNewswire
Zevra Therapeutics Announces Positive Data for MIPLYFFA® in Niemann-Pick Disease Type C at ICIEM; Poster Nominated for Best Award - Quiver Quantitative
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewswire
Disease Progression Slowed: Zevra's MIPLYFFA Shows Breakthrough Results in Rare Niemann-Pick Disease Trial - Stock Titan
How does Zevra Therapeutics Inc. compare to its peersMarket Sentiment Review & AI Driven Stock Price Forecasts - خودرو بانک
What makes Zevra Therapeutics Inc. stock price move sharplyJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Tools to monitor Zevra Therapeutics Inc. recovery probabilityEarnings Growth Report & High Return Stock Watch Alerts - Newser
Can you recover from losses in Zevra Therapeutics Inc.Weekly Market Report & Low Drawdown Momentum Ideas - Newser
Zevra Therapeutics at Cantor Conference: Rare Disease Strategy Unveiled By Investing.com - Investing.com Canada
Fund Flows: What is Zevra Therapeutics Inc.’s market positionProfit Target & Fast Momentum Stock Entry Tips - خودرو بانک
Zevra Therapeutics at Cantor Conference: Rare Disease Strategy Unveiled - Investing.com
Does Zevra Therapeutics Inc. meet Warren Buffett’s criteria2025 Market Overview & Weekly Chart Analysis and Trade Guides - خودرو بانک
Predicting Zevra Therapeutics Inc. trend using moving averages2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Zevra Therapeutics Inc. stock chart pattern explained2025 Retail Activity & Verified Entry Point Signals - Newser
How to manage a losing position in Zevra Therapeutics Inc.2025 Winners & Losers & Fast Exit and Entry Strategy Plans - Newser
Can Zevra Therapeutics Inc. recover in the next quarterChart Signals & Community Trade Idea Sharing Platform - Newser
Relative strength of Zevra Therapeutics Inc. in sector analysisTrade Risk Summary & Comprehensive Market Scan Insights - Newser
Zevra Therapeutics, Inc. $ZVRA is Velan Capital Investment Management LP's 9th Largest Position - MarketBeat
Is Zevra Therapeutics Inc. still worth holding after the dipJuly 2025 Decliners & Smart Investment Allocation Insights - Newser
Full technical analysis of Zevra Therapeutics Inc. stock2025 Key Highlights & Reliable Price Breakout Signals - Newser
Advanced analytics toolkit walkthrough for Zevra Therapeutics Inc.Jobs Report & Growth Oriented Trading Recommendations - Newser
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):